Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase

A potent protective effect of baicalein on liver injury by regulating mitochondria-related apoptosis

(2020) Zhongjie Yu et al.   APOPTOSIS

Dual actions of norathyriol as a new candidate hypouricaemic agent: uricosuric effects and xanthine oxidase inhibition

(2019) Hua Lin et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016–2019)

(2019) Yue Dong et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis

(2018) Nicola Dalbeth et al.   ANNALS OF THE RHEUMATIC DISEASES

The anti-hyperuricemic effect of epigallocatechin-3-gallate (EGCG) on hyperuricemic mice

(2018) Chuang Zhu et al.   BIOMEDICINE & PHARMACOTHERAPY

Inhibition mechanism of baicalein and baicalin on xanthine oxidase and their synergistic effect with allopurinol

(2018) Ni Zeng et al.   Journal of Functional Foods

Baicalein acts as a nephroprotectant that ameliorates colistin-induced nephrotoxicity by activating the antioxidant defence mechanism of the kidneys and down-regulating the inflammatory response

(2017) Chongshan Dai et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Identification and characterization of a potent and selective inhibitor of human urate transporter 1

(2017) Ting Wu et al.   Pharmacological Reports

Baicalin and baicalein attenuate renal fibrosis in vitro via inhibition of the TGF-β1 signaling pathway

(2017) Qin Hu et al.   Experimental and Therapeutic Medicine

Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice

(2017) Xiaolu Meng et al.   Oncotarget

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout

(2017) Philip K. Tan et al.   Scientific Reports

Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model

(2016) Jianbiao Peng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Gout

(2016) Nicola Dalbeth et al.   LANCET

Serum uric acid and the risk of cardiovascular and renal disease

(2015) Claudio Borghi et al.   JOURNAL OF HYPERTENSION

A Review of Uric Acid, Crystal Deposition Disease, and Gout

(2014) Fernando Perez-Ruiz et al.   ADVANCES IN THERAPY

Discovery of xanthine oxidase inhibitors from a complex mixture using an online, restricted-access material coupled with column-switching liquid chromatography with a diode-array detection system

(2014) De-qiang Li et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Effect of luteolin on xanthine oxidase: Inhibition kinetics and interaction mechanism merging with docking simulation

(2013) Jiakai Yan et al.   FOOD CHEMISTRY

Serum Uric Acid Levels and the Risk of Type 2 Diabetes: A Prospective Study

(2010) Vidula Bhole et al.   AMERICAN JOURNAL OF MEDICINE

Homozygous SLC2A9 Mutations Cause Severe Renal Hypouricemia

(2009) D. Dinour et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Plasma Urate Level Is Directly Regulated by a Voltage-driven Urate Efflux Transporter URATv1 (SLC2A9) in Humans

(2008) Naohiko Anzai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY